Loading...
Reneo Pharmaceuticals, Inc.
RPHM•NASDAQ
HealthcareBiotechnology
$18.20
$16.47(952.02%)
Reneo Pharmaceuticals, Inc. (RPHM) Stock Overview
Explore Reneo Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for RPHMStats details for RPHM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for RPHMAnalyst Recommendations details for RPHM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
CEO
Mr. Gregory J. Flesher
Employees
8
Headquarters
18575 Jamboree Road, Irvine, CA
Founded
2021